EUVIMEDEUVIMED entdecken
Crossref

Molecular epidemiology of human papillomavirus genotypes among HIV-negative women and women living with HIV with cervical cancer in two regions in Nigeria

Chuwang J Nyam iD, Jonah Musa, Brian T Joyce, Kyeezu Kim, Jun Wang, Stefan J Green, Demirkan B Gursel, Fatimah Abdulkareem, Alani S Akanmu, Olugbenga A Silas, Godwin E Imade, Rose Anorlu und 5 weitere

International Journal of STD & AIDS · 2025

DOI: 10.1177/09564624251362592 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of STD & AIDS, 2025. Verfasst von Chuwang J Nyam und 16 weiteren Autor:innen. Beteiligte Einrichtung: Genomics and Postgraduate Core Facility, College of Health Sciences, University of Jos, Jos, Nigeria. Hauptthemen laut MEDLINE: Papillomavirus Infections, HIV Infections, Uterine Cervical Neoplasms, Papillomaviridae. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: FIC NIH HHS, NCI NIH HHS, Fogarty International Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cervical cancer (CC) is highly prevalent in Nigeria, with over 12,000 cases and 8000 deaths annually. Differences in diagnostic methods for human papillomavirus (HPV) genotypes have generated varied prevalence rates across populations.

Methods

We analyzed the prevalence and distribution of high-risk HPV (HR-HPV) genotypes among women with CC, comparing HIV-negative women and women living with HIV (WLWH), using data from a prospective Nigerian cohort study (2018–2022). High-throughput next-generation sequencing (NGS) of the HPV L-1 gene identified and classified genotypes.

Results

Among 189 women tested for HR-HPV, 74.1% (140/189) were HIV-negative, and 25.9% (49/189) were WLWH. The median age was lower for WLWH at 48 years [IQR: 41–54] compared to HIV-negative women at 60 years [IQR: 49–69] ( p < .001). The overall prevalence of HR-HPV was 64.6% (122/189; 95% CI: 57.4–71.1), with higher rates in WLWH (77.6%, 38/49) than HIV-negative women (60.0%, 84/140) ( p < .001). Among HR-HPV-positive cases, HPV16 or HPV18 accounted for the highest proportion, representing 67.2% (95% CI: 58.3–75.0). The most prevalent HR-HPV types detected were HPV16 (46.7%), HPV18 (20.5%), HPV45 (9.8%), HPV35 (6.6%), and HPV52 (5.7%). Quadrivalent and nonavalent HPV vaccines would cover 67.2% (95% CI: 58.3–75.0) and 86.1% of HR-HPV infections, respectively.

Conclusion

Our NGS approach findings among women with CC identified HPV types not covered by the Gardasil-4 vaccine used in Nigeria. This highlights the need for broader vaccine coverage against most HR-HPV types, regardless of HIV status, in Nigeria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus InfectionsHIV InfectionsUterine Cervical NeoplasmsPapillomaviridaeHumansFemaleNigeriaMiddle AgedAdultGenotypePrevalenceProspective StudiesMolecular EpidemiologyHigh-Throughput Nucleotide SequencingHIV SeronegativityAgedDNA, ViralHuman Papillomavirus Viruses

Stichwörter der Autor:innen

Cervical cancerHR-HPVNGSNigeriavaccine coverage

Substanzen

DNA, Viral

Autor:innen und Institutionen

  • Genomics and Postgraduate Core Facility, College of Health Sciences, University of Jos, Jos, Nigeria.
  • Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago, Chicago, IL, USA.
  • Department of Obstetrics and Gynecology, College of Health Sciences, University of Jos, Jos, Nigeria.
  • Department of Preventive Medicine, Division of Cancer Epidemiology and Prevention, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
  • Center for Global Oncology, Institute for Global Health, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
  • Department of Social and Preventive Medicine, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.

ORCID-Profile: Chuwang J Nyam, Supriya D Mehta

Förderung

  • FIC NIH HHS
  • NCI NIH HHS
  • Fogarty International Center
  • Division of Cancer Prevention, National Cancer Institute

Zitieren

APA

Nyam, C. J., Musa, J., Joyce, B. T., Kim, K., Wang, J., Green, S. J., Gursel, D. B., Abdulkareem, F., Akanmu, A. S., Silas, O. A., Imade, G. E., Anorlu, R., Ogunsola, F., Sagay, A. S., Murphy, R. L., Hou, L., & Mehta, S. D. (2025). Molecular epidemiology of human papillomavirus genotypes among HIV-negative women and women living with HIV with cervical cancer in two regions in Nigeria. International Journal of STD & AIDS. https://doi.org/10.1177/09564624251362592

Vancouver

Nyam CJ, Musa J, Joyce BT, Kim K, Wang J, Green SJ, et al. Molecular epidemiology of human papillomavirus genotypes among HIV-negative women and women living with HIV with cervical cancer in two regions in Nigeria. International Journal of STD & AIDS. 2025. doi:10.1177/09564624251362592

BibTeX
@article{Nyam2025,
  author = {Nyam, Chuwang J and Musa, Jonah and Joyce, Brian T and Kim, Kyeezu and Wang, Jun and Green, Stefan J and Gursel, Demirkan B and Abdulkareem, Fatimah and Akanmu, Alani S and Silas, Olugbenga A and Imade, Godwin E and Anorlu, Rose and Ogunsola, Folasade and Sagay, Atiene S and Murphy, Robert L and Hou, Lifang and Mehta, Supriya D},
  title = {Molecular epidemiology of human papillomavirus genotypes among HIV-negative women and women living with HIV with cervical cancer in two regions in Nigeria},
  journal = {International Journal of STD & AIDS},
  year = {2025},
  doi = {10.1177/09564624251362592}
}
Kostenlos starten →